GALECTIN THERAPEUTICS INC
Norcross, Georgia, United States · Biotechnology, Healthcare, Health Care
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U
Key facts
- Headquarters
- Norcross, Georgia, United States
- Employees
- 15
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (GALT)
- Website
- galectintherapeutics.com
- Company page
Recent activity at GALECTIN THERAPEUTICS INC
- : Galectin Therapeutics Raises Capital Through Conversion of Convertible Notes
- : SEC 8-K (1.01): On December 19, 2025, Galectin Therapeutics Inc. entered into a Line of Credit Letter Agreement with Richard E. Uihlein, allowing for a line of credit of up to $10 million to finance the Company's working capital needs. The agreement enables the Company to draw upon the line of credit until January 31, 2027, with each advance secured by an unsecured, convertible promissory note. The interest on the promissory notes will be set at the Applicable Federal Rate for short term loans (currently 3.60%) plus an additional 2%. This agreement provides significant financial backing for the Company's operational activities in the near future.
- : Galectin Therapeutics Appoints Khurram Jamil, M.D. as Vice President, Clinical Development
- : GALECTIN THERAPEUTICS INC
- : GALECTIN THERAPEUTICS INC
- : GALECTIN THERAPEUTICS INC
GALECTIN THERAPEUTICS INC funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series A | $81.0M |
| Jan 2017 | Seed | $3.0M |
| Sep 2016 | Seed | $1.5M |
| Dec 2015 | Venture | Undisclosed |
Leadership
- Sharisse, Senior Director Project Management
- Theodore Zuconni, Director
- Marc Rubin, Director
- Steven Prelack, Director
- Gilbert Omenn, Director
- John Mauldin, Director
- Kevin Freeman, Director
- Arthur Greenberg, Director
- Gilbert Amelio, Director
- James Czirr, Director
- Peter Traber, Executive Officer, Director
- Marc Rubin, Director
Verified email and direct lines for GALECTIN THERAPEUTICS INC’s decision-makers are on Fundz. See plans
Employee benefit plans
GALECTIN THERAPEUTICS INC files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
GALECTIN THERAPEUTICS INC in the news
- Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update - Yahoo Finance (May 15, 2026)
- A drug company will present in New York Sept. 14. Galectin will meet investors there. - Stock Titan (Sep 10, 2026)
- Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - Yahoo Finance (Jun 23, 2026)
- Galectin Therapeutics (GALT) Stock Price, News & Analysis $GALT - MarketBeat (Jun 05, 2015)
- Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - Yahoo Finance (Aug 14, 2026)
- Galectin Therapeutics, Inc. (GALT) stock price, news, quote and history - Yahoo Finance UK (May 18, 2017)
Companies similar to GALECTIN THERAPEUTICS INC
- Adial Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
- Galecto · Biotechnology, Healthcare, Health Care, Therapeutics
- Cocrystal Pharma, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Aarvik Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- BiomX · Biotechnology, Healthcare, Health Care, Therapeutics
About GALECTIN THERAPEUTICS INC: questions and answers
What does GALECTIN THERAPEUTICS INC do?
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U
Where is GALECTIN THERAPEUTICS INC headquartered?
GALECTIN THERAPEUTICS INC is headquartered in Norcross, Georgia, United States.
How many employees does GALECTIN THERAPEUTICS INC have?
GALECTIN THERAPEUTICS INC has about 15 employees.
Has GALECTIN THERAPEUTICS INC raised funding?
Yes. Fundz has recorded 4 funding events for GALECTIN THERAPEUTICS INC. The most recent, Series A of $81.0M, was in Jul 2026.
What is the latest news on GALECTIN THERAPEUTICS INC?
On Jul 31, 2026, Galectin Therapeutics Raises Capital Through Conversion of Convertible Notes
Is GALECTIN THERAPEUTICS INC a public company?
Yes. GALECTIN THERAPEUTICS INC is publicly traded under the ticker GALT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy